A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Newly Diagnosed Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Daratumumab

Sponsor

GlaxoSmithKline